Yahoo
NasdaqGM - Nasdaq Real Time Price USD

Rani Therapeutics Holdings, Inc. (RANI)

0.5900 -0.0154 (-2.54%)
At close: October 30 at 4:00:00 PM EDT
0.6011 +0.0111 (+1.88%)
After hours: October 30 at 7:29:10 PM EDT
View in AlphaSpace Currency in USD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
4,877
1,633
1,028
0
0
Operating Expense
37,836
39,943
50,628
66,099
63,451
Operating Income
-32,959
-38,310
-49,600
-66,099
-63,451
Net Non Operating Interest Income Expense
111
-2,064
-3,270
-1,784
177
Other Income Expense
--
-576
-3,714
--
--
Pretax Income
-33,424
-40,950
-56,584
-67,883
-63,274
Tax Provision
--
--
--
0
70
Net Income Common Stockholders
-30,141
-29,673
-30,018
-33,970
-30,588
Diluted NI Available to Com Stockholders
-30,141
-29,673
-30,018
-33,970
-30,588
Basic EPS
-0.13
-0.45
-1.05
-1.33
-1.28
Diluted EPS
-0.13
-0.45
-1.05
-1.33
-1.28
Basic Average Shares
138,657.5000
66,138
28,476
25,505
23,817
Diluted Average Shares
138,657.5000
66,138
28,476
25,505
23,817
Total Operating Income as Reported
-32,959
-38,310
-53,314
-66,099
-63,451
Total Expenses
37,836
39,943
50,628
66,099
63,451
Net Income from Continuing & Discontinued Operation
-30,141
-29,673
-30,018
-33,970
-30,588
Normalized Income
-29,565
-29,097
-26,304
-33,970
-30,588
Interest Income
1,279
827
1,763
3,301
1,248
Interest Expense
1,168
2,891
5,033
5,085
1,071
Net Interest Income
111
-2,064
-3,270
-1,784
177
EBIT
-32,256
-38,059
-51,551
-62,798
-62,203
EBITDA
-31,534
-37,159
-50,523
-61,976
-61,655
Reconciled Depreciation
722
900
1,028
822
548
Net Income from Continuing Operation Net Minority Interest
-30,141
-29,673
-30,018
-33,970
-30,588
Total Unusual Items Excluding Goodwill
-576
-576
-3,714
0
0
Total Unusual Items
-576
-576
-3,714
0
0
Normalized EBITDA
-30,958
-36,583
-46,809
-61,976
-61,655
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2022 - 7/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: